|Protocol Summary||Back To Search Instructions|
|Protocol No.||E1910||Principal Investigator||Baer, Maria|
|Title||A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults|
|Description||Eligible patients will be placed (by chance) into 1 of 2 groups: 1) Blinatumomab with standard of care therapies OR 2) Standard of care therapies alone.
Patients who have no response after induction chemotherapy will be taken off treatment. Patients who acheive some remission will have intensification chemotherapy. After intensification chemotherapy, some patients will take blinatumomab. All subjects will then continue to receive standard of care cancer treatments. Patients in the blinatumomab group may receive up to 2 additional cycles of blinatumomab. All patients will be followed while taking maintenance chemotherapy.
|Treatment||Blinatumomab and standard chemotherapy OR Standard Chemotherapy alone|
|Key Eligibility||--35 to 70 years old
--No Mature B ALL is allowed
--Negative for the Philadelphia chromosome
--No other cancers which are under treatment
--Normal heart and organ function
|Applicable Disease Sites||Acute Lymphocytic Leukemia|
|Therapies Involved||Chemotherapy (NOS)
Cytarabine (Cytosine Arabinoside)
|Contact||Greenebaum Comprehensive Cancer Center: Nicole Glynn-Cunningham, MS||
|Back to Protocol Listing|